NEW YORK (GenomeWeb) – LGC's recent acquisition of Douglas Scientific, approximately one year after it acquired Biosearch Technologies, have bolstered the UK firm's PCR and molecular diagnostics product portfolios and effectively doubled the size of its genomics division.

In addition, US-based Douglas and Biosearch, have helped establish North America as an axis of operations for LGC's genomics business, Giulio Cerroni, LGC's managing director, told GenomeWeb this week.